11:33 AM EDT, 06/18/2024 (MT Newswires) -- Cosmos Health ( COSM ) said Tuesday it has agreed to acquire all remaining rights associated with the patent filed with the World Intellectual Property Organization for a drug targeting central nervous system cancers.

Financial terms weren't disclosed.

This continues from the agreement disclosed on Dec. 7, 2023, when Cosmos Health ( COSM ) acquired 60% of the rights to the patent from Cloudpharm, which focuses on repurposing a drug aimed at treating specific conditions such as central nervous system cancers, hematological cancers, allergic inflammation, and autoimmune diseases, the company said.

Shares of Cosmos Health ( COSM ) were up 13% in recent Tuesday trading.

Price: 0.75, Change: +0.05, Percent Change: +7.30